Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 4,911 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jon Coleman sold 4,911 shares of DexCom stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares in the company, valued at approximately $7,075,708.50. This represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Coleman also recently made the following trade(s):

• On Wednesday, June 3rd, Jon Coleman sold 4,912 shares of DexCom stock. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00.

DexCom Stock Up 0.4%

Shares of DXCM traded up $0.27 on Friday, reaching $72.86. The stock had a trading volume of 4,672,514 shares, compared to its average volume of 5,348,739. The firm has a market capitalization of $28.11 billion, a price-to-earnings ratio of 31.14, a price-to-earnings-growth ratio of 1.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The company has a 50-day simple moving average of $64.71 and a 200-day simple moving average of $66.94. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm posted $0.32 EPS. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. Sell-side analysts predict that DexCom, Inc. will post 2.57 EPS for the current year.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Avidity Partners Management LP purchased a new stake in DexCom during the 1st quarter valued at $5,652,000. Glenmede Trust Co. NA grew its holdings in shares of DexCom by 36.7% in the first quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company’s stock worth $24,790,000 after acquiring an additional 105,928 shares during the period. Wellington Grp LLC grew its holdings in shares of DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares during the period. Janus Henderson Group PLC increased its position in DexCom by 32.3% during the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after acquiring an additional 645,534 shares during the last quarter. Finally, Centaurus Financial Inc. bought a new position in DexCom in the first quarter valued at about $943,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on DXCM shares. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research note on Friday, May 1st. Wells Fargo & Company cut their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Robert W. Baird set a $80.00 price objective on shares of DexCom in a report on Friday, May 1st. BTIG Research reiterated a “buy” rating and set a $85.00 target price on shares of DexCom in a research note on Monday, March 9th. Finally, Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $82.63.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.